tbuckley/cabot-search huggingface dataset:
P105 Lung cancer staging – are we getting it right?
Authors: J Ibrahim, A Mukhopadhyay, V Lostarakos, A Mahmood, S Khan, N Maddekar, S Bikmalla, A Lea, C Satur, Q Abid, S Ghosh, M Haris
Journal: Thorax (2016)

<h3>Introduction</h3> Despite significant advances in the diagnostic and staging modalities, lung cancer survival remains poor. Accurate staging and stratification of lung cancer is imperative to appropriate management. We reviewed the accuracy of staging in all patients who underwent surgical resection for confirmed or suspected lung cancer. <h3>Methods</h3> Retrospective study of consecutive surgical resections over 5 year period between January 2010 and December 2014; patients referred from other hospitals were excluded due to lack of pre-operative staging information. Surgical database and pre-operative diagnostic information was reviewed. <h3>Results</h3> 298 patients underwent surgical resection, mean age 68 years (range 26–91), male 150 (50%). All patients had staging CT. 108 (36%) had EBUS/Bronchoscopy, 9 (3%) had pleural aspiration, 39 (13%) had CT guided lung biopsy, 8 (3%) other tissue sampling* (pelvic lesion, subcutaneous lymph node, previous wedge biopsy &amp; exploratory thoracotomy). Mean time from staging CT to resection was 47 days. 48 (16%) had histo-cytological confirmation of lung cancer prior to resection. 248 (83%) were primary lung, 17 (6%) metastatic lung tumours from other primaries (breast, colorectal, bladder and renal), 2 (1%) lymphoma and 31 (10%) benign. Of the 248 patients with lung primary (see Figure 1), pre-operative staging was available in 234; 60/234 (26%) were down staged on post-operative staging, 54 (23%)) upstaged and 120 (51%) showed concordance. <h3>Conclusion</h3> Despite the use of combined pre-operative assessment, staging accuracy was only 51% and histo-cytological confirmation of lung cancer was only available in a small number of patients. Every effort should be made by the multidisciplinary team to accurately stage lung cancer to guide appropriate therapeutic intervention.
Treatment of Low-Grade Non-Hodgkin Lymphomas with Fludarabine and Mitoxantrone Followed by Rituximab Maintenance: Results of a Phase II Study.
Authors: Amanda Psyrri, Meletios A. Dimopoulos, George Fountzilas, Constantinos Tsatalas, Athanasios Anagnostopoulos, Sotirios Papageorgiou, Nikolaos Xiros, Theofanis Economopoulos
Journal: Blood (2006)
Chemoimmuno-Therapy with Fludarabine, Cyclophosphamide and Alemtuzumab in Patients with Relapsed/Refractory CLL: Interim Analysis of the CLL2L Trial of the German CLL Study Group
Authors: Thomas Elter, Rojin James, Stephan Stilgenbauer, Matthias Ritgen, Michael Hallek, Andreas Engert
Journal: Blood (2008)
Electromagnetic Interference in Cardiac Implantable Electronic Devices
Authors: Carsten Lennerz, Herribert Pavaci, Christian Grebmer, Verena Semmler, Felix Bourier, Bernhard Haller, Tilko Reents, Gabriele Hessling, Isabel Deisenhofer, Christof Kolb
Journal: Journal of the American College of Cardiology (2017)
The expression of GATA-3 and FOXA1 in breast cancer: The biomarkers of hormone sensitivity in luminal-type tumors.
Authors: Y. Hisamatsu, E. Tokunaga, S. Akiyoshi, S. Okada, N. Yamashita, E. Oki, M. Morita, Y. Kakeji, Y. Maehara
Journal: Journal of Clinical Oncology (2011)

599 Background: The assessment of the needs of the adjuvant chemotherapy has been the important problem in luminal type breast cancers. Multigene prognosis assays such as Oncotype Dx and Mammaprint, turned out to be efficient techniques. However, these assays are expensive and have not been prospectively validated. The transcription factors GATA-binding protein 3 (GATA-3) and Forkhead-box protein A1 (FOXA1) function with estrogen receptor α (ERα) in mammary morphogenesis. These transcription factors form an autoregulatory hormonal network that influences estrogen responsiveness and sensitivity to hormonal therapy. Methods: We analyzed GATA-3 and FOXA1 expression in 307 primary breast cancers by immunohistochemistry, to evaluate the association with breast cancer molecular markers, clinicopathological features and patients’ recurrence-free survival. We classified the cases into luminal A and B using hormonal receptors, HER2 and Ki67 index (cut-off value: 14%). Results: 1.GATA-3 expression was positively correlated with FOXA1 (p<0.0001). 2. GATA-3 and FOXA1 were positively correlated with ER and PgR (both p<0.0001), and inversely correlated with nuclear grade (both p<0.0001) and Ki 67 index (p=0.0003 and p<0.0001). 3. GATA-3 expression was correlated with better prognosis in luminal B cases (p=0.0013), but no relationship was found in luminal A cases. Whereas, FOXA1 was correlated with better prognosis in both luminal A (p=0.0010) and B cases (P=0.0005). Besides, FOXA1 expression influenced prognosis in the cases with high GATA-3 expression in both luminal A (p=0.0011) and B (p=0.0202) cases who received hormonal therapy, whereas GATA-3 expression had no influence on prognosis in the cases with high FOXA1 expression. 4. High FOXA1 expression was also an independent favorable prognostic factor by multivariate analysis in not only all cases but also luminal type cases. GATA-3 was not recognized as an independent prognostic factor in either case. Conclusions: Our study suggests that GATA-3 and FOXA1 are associated with hormonal sensitivity and prognosis. These data also demonstrates that the expression of FOXA1 can be more useful than GATA-3 as a biomarker in luminal type cases.
Host Genetic Background and Risk of Richter Syndrome: The Genotype of LRP4 Is An Independent Predictor of Chronic Lymphocytic Leukemia Transformation to Aggressive Lymphoma.
Authors: Davide Rossi, Silvia Rasi, Claudio Tripodo, Francesco Forconi, Luca Laurenti, Alessio Bruscaggin, Marco Fangazio, Alessia Puma, Elisa Sozzi, Jeffrey T. Malik, Josep F. Nomdedeu, Roberto Marasca, Valter Gattei, Ken H. Young, Stefano A. Pileri, Francesco Lauria, Fabio Malavasi, Silvia Deaglio, Gianluca Gaidano
Journal: Blood (2009)
Intracellular Cleavable CpG Oligodeoxynucleotide-Antigen Conjugate Enhances Anti-tumor Immunity
Authors: Katrin Kramer, Nicholas J. Shields, Viola Poppe, Sarah L. Young, Greg F. Walker
Journal: Molecular Therapy (2017)

Conjugation of a vaccine adjuvant to an antigen enhances anti-tumor immune responses. Direct chemical conjugation, however, may limit their processing by the antigen-presenting cell for immune stimulation. To test this hypothesis, antigen-adjuvant conjugates were designed to be cleaved by an intracellular trigger to release antigen and adjuvant from each other. The different reductive environment inside and outside antigen-presenting cells was used as a trigger for targeted intracellular release. Two redox-responsive disulphide linkers were used to conjugate the model antigen ovalbumin to CpG. In vitro stability assays with the reductant glutathione showed that one conjugate (SS) was cleaved by glutathione concentrations of the extra- and intracellular compartments. A second conjugate (HYN-SS) was only cleaved at the higher intracellular glutathione concentration. In vitro cell culture studies showed that high T cell responses were generated by the HYN-SS and the stable conjugate HYN. The SS conjugate induced a lower T cell response similar to a mixture of CpG and ovalbumin. An in vivo therapeutic tumor trial demonstrated a superior survival rate of 9/10 for mice vaccinated with HYN-SS conjugate compared to HYN (6/10), SS (2/10), and the mixture (2/10). This intracellular cleavable conjugation strategy represents a promising approach to improve cancer immunotherapy of soluble vaccines.
Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn's disease
Authors: James C Lee, Daniele Biasci, Rebecca Roberts, Richard B Gearry, John C Mansfield, Tariq Ahmad, Natalie J Prescott, Jack Satsangi, David C Wilson, Luke Jostins, Carl A Anderson, James A Traherne, Paul A Lyons, Miles Parkes, Kenneth G C Smith
Journal: Nature Genetics (2017)
S122 Effects of vaped e-cigarette liquid condensate upon human alveolar macrophage function. to vape or not to vape that is the question?
Authors: A Scott, ST Lugg, V D’Souza, K Lewis, D Dosanjh, B Naidu, DR Thickett
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> Electronic cigarette usage or “vaping” has risen exponentially in recent years in smokers and ex-smokers. Published data suggests that vaping e-cigarette liquid (ECL) may not be as benign as propounded by e-cigarette companies which are increasingly owned by “big tobacco”. Much of the current literature has focused on the effect of non-vaporised ECL – such studies do not fully reflect the exposure of the user, as the process of vaping causes chemical changes in ECL. To investigate the effect of unvaped ECL and vaped e-cig condensate (ECVC) using our novel system, with and without nicotine, on alveolar macrophage (AM) viability and immune responses. <h3>Methods</h3> We developed a novel method to produce ECVC to allow direct comparison with unvaped ECL. Nicotine concentration as assessed by GFID was 31 mg/ml in ECL and 26 mg/ml in ECVC. AMs were obtained from lung resection tissue and treated with ECVC/ECL ± nicotine. Cell viability was assessed by cell titre aqueous assay, apoptosis, necrosis and markers of macrophage phenotype (CD68, CD80, CD163, CD206) were assessed by flow cytometry. IL-8 release by AMs was assessed by ELISA. <h3>Results</h3> AM culture with ECL or ECVC resulted in dose dependent reduction in cell viability. ECVC was cytotoxic at lower concentrations than ECL (0.8% ECVC vs 5 %ECL, n = 6). 24 hour culture with 1% ECVC resulted in a 5fold increase in AM apoptosis and 2 fold increase in necrosis compared with 1%ECL (p = 0.079, n = 5). Nicotine containing ECVC caused more apoptosis vs nicotine free ECVC (27.2% vs 13.4%, (p = 0.0079,n = 4). Culture with 0.6%ECVC significantly increased supernatant levels of IL-8 compared with 1% ECL (p = 0.015, n = 4). ECVC was also found to affect macrophage phenotype, showing both nicotine dependent/independent regulations of markers of macrophage m1/m2 polarisation (CD80 p = 0.0357, CD163 p = 0.0179, CD206 p = 0.0357, n = 6). <h3>Conclusions</h3> Our novel system creates ECVC which is sterile, minimises loss of nicotine and prevents dilution of the vapour. Vaped E-cigarette condensate is significantly more toxic to AMs than non-vaped e cigarette liquid. Furthermore, ECVC with nicotine is significantly more toxic than ECVC without Nicotine. Effects shown on inflammatory cytokine production and markers of macrophage polarisation indicate both nicotine dependent and independent effects of ECVC on alveolar macrophages.
P3.02b-028 Characterizing Residual Erlotinib-Tolerant Population Using EGFR-Mutated NSCLC Primary Derived Xenografts: The Last Holdouts
Authors: Erin Stewart, Michael Cabanero, Nhu-An Pham, Shu Yi Shen, Tiantian Li, Jeff Bruce, Ming Li, Natasha Leighl, Frances Shepherd, Trevor Pugh, Daniel De Carvalho, Mathieu Lupien, Geoffrey Liu, Ming Tsao
Journal: Journal of Thoracic Oncology (2017)
Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases–sponsored expert panel
Authors: Alkis Togias, Susan F. Cooper, Maria L. Acebal, Amal Assa'ad, James R. Baker, Lisa A. Beck, Julie Block, Carol Byrd-Bredbenner, Edmond S. Chan, Lawrence F. Eichenfield, David M. Fleischer, George J. Fuchs, Glenn T. Furuta, Matthew J. Greenhawt, Ruchi S. Gupta, Michele Habich, Stacie M. Jones, Kari Keaton, Antonella Muraro, Marshall Plaut, Lanny J. Rosenwasser, Daniel Rotrosen, Hugh A. Sampson, Lynda C. Schneider, Scott H. Sicherer, Robert Sidbury, Jonathan Spergel, David R. Stukus, Carina Venter, Joshua A. Boyce
Journal: Journal of Allergy and Clinical Immunology (2017)
Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
Authors: M. Angelyn Bethel, Samuel S. Engel, Jennifer B. Green, Zhen Huang, Robert G. Josse, Keith D. Kaufman, Eberhard Standl, Shailaja Suryawanshi, Frans Van de Werf, Darren K. McGuire, Eric D. Peterson, Rury R. Holman
Journal: Diabetes Care (2017)

OBJECTIVE Limited data exist regarding safety and efficacy of antihyperglycemic drugs in older patients with type 2 diabetes. The Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) was a randomized, double-blind, placebo-controlled trial assessing the impact of sitagliptin on a primary composite outcome of cardiovascular death, nonfatal stroke, nonfatal myocardial infarction, or unstable angina hospitalizations in patients with type 2 diabetes (HbA1c ≥6.5% [48 mmol/mol] and ≤8.0% [64 mmol/mol]) and cardiovascular disease. We analyzed baseline characteristics and clinical outcomes for TECOS participants aged ≥75 years. RESEARCH DESIGN AND METHODS Clinical and safety event summaries are presented for older versus younger participants and for the treatment groups within the older cohort. RESULTS Of 14,351 participants with age recorded, 2,004 (14%) were ≥75 years old (mean age 78.3 years [SD 3.1]), with 68% men and type 2 diabetes duration median 12.0 years (IQR 7, 21). During 2.9 years median follow-up, older participants had higher rates of the primary outcome (6.46 vs. 3.67 events per 100 person-years; hazard ratio 1.72 [95% CI 1.52–1.94]), death (2.52 [2.20–2.89]), severe hypoglycemia (1.53 [1.15–2.03]), and fractures (1.84 [1.44–2.35]). In the older cohort, sitagliptin did not significantly impact the primary composite (1.10 [0.89–1.36]), death (1.05 [0.83–1.32]), heart failure hospitalization (0.99 [0.65–1.49]), severe hypoglycemia (1.03 [0.62–1.71]), rates of acute pancreatitis and pancreatic cancer, or serious adverse events. CONCLUSIONS Among older patients with well-controlled type 2 diabetes and cardiovascular disease, sitagliptin had neutral effects on cardiovascular risk and raised no significant safety concerns.
Durable Local Disease Control and Survival in Patients with Limited-Stage Diffuse Large B-Cell Lymphoma Receiving Involved-Node Radiation Therapy Plus Short-Course R-CHOP or CHOP Chemotherapy: Involved-Node Versus Involved-Field Radiation Therapy
Authors: Harumi Kato, Takeshi Kodaira, Kazuhito Yamamoto, Yukihiko Oshima, Yasuhiro Oki, Hiroyuki Tachibana, Hirofumi Taji, Satsuki Murakami, Daiki Hirano, Natsuo Tomita, Yasushi Yatabe, Shigeo Nakamura, Tomohiro Kinoshita
Journal: Blood (2012)
P107 Predictors of mortality in patients undergoing lung cancer surgery
Authors: H Law, P Foden, M Evison, F Wallace, A Ashworth, R Shah, P Crosbie, R Booton
Journal: Thorax (2016)

<h3>Introduction</h3> Surgical resection is a treatment of choice for patients with early stage lung cancer and physiological measurements are routinely used to help predict post-operative risk, particularly in the ‘high-risk’ patient group. At present, there is a lack of concordance between current available guidelines incorporating the use of such parameters aimed to guide decisions on surgery for high-risk patients with lung cancer. As a result, the decision to operate will differ for a particular patient depending on which guidelines are consulted. We aim to identify which parameters best predicts post-operative mortality and whether this information can be used to construct a more encompassing pre-operative risk prediction model to help guide these difficult decision processes. <h3>Methods</h3> Retrospective analysis of all patients undergoing CPET (cardio-pulmonary exercise testing) prior to lung cancer surgery between 01/01/2012 and 31/12/2015 was carried out. Age, BMI along with pre-operative and post-operative predicted physiological parameters were reviewed and statistical analysis performed. We also looked at survival based on type of surgery (sub-lobar, lobar, pneumonectomy), histology and cancer staging. <h3>Results</h3> Single variable analysis of the 178 patients identified that low BMI (p = 0.005) and PPO DLCO% (p = 0.004) were associated with greater post-operative mortality risk. There was a statistically significant difference between different cancer stage and type of surgery as expected. Using the probabilities from the logistical regression model to predict one-year mortality gives an AUC of 0.764. A probability cut-off of 0.167 used to predict whether a patient will die within one year of surgery provides a sensitivity of 76.5%, specificity 66.4%, PPV 35.1% and NPV 92.2%. <h3>Conclusions</h3> Contrary to current guidelines, CPET data did not seem to carry statistically significant weighting in determining post-operative mortality outcomes in our patient group with BMI and PPO DLCO% showing a stronger, statistically significant association. Absolute% change between pre and PPO FEV1 values appears to be a good predictor of one-year mortality following surgery. Further work is required but early analysis suggested that parameters such as BMI, PPO DLCO% and absolute post-operative change in FEV1% can be used to construct a pre-surgical prediction model for ‘high-risk’ patients undergoing surgery for lung cancer.
P28 Chronic thromboembolic pulmonary hypertension: long term outcomes in surgical and non-surgical patients
Authors: SR Quadery, RA Condliffe, C Billings, R Thompson, CA Elliot, A Charalampopolous, J Hurdman, N Hamilton, I Armstrong, P Sephton, I Sabroe, A Swift, J Wild, DG Kiely
Journal: Thorax (2016)

<h3>Introduction</h3> Chronic thromboembolic pulmonary hypertension (CTEPH) is commonly associated with a history of venous thromboembolism. Pulmonary endarterectomy (PEA) offers a potential cure in surgically accessible disease. However, a significant proportion of patients with CTEPH may not undergo surgery due to various reasons including disease distribution, comorbidities and patient choice This group of patients have previously been considered to have a poor outcome although an international registry has recently reported on improved medium term outcomes in this patient population. <h3>Aims and objectives</h3> To compare long term survival of patients with CTEPH undergoing pulmonary endarterectomy (CTEPH-surgical-operated), surgically accessible disease not undergoing pulmonary endarterectomy (CTEPH-surgical-not-operated), surgically inaccessible disease (CTEPH-non-surgical). <h3>Methods</h3> Data was retrieved from hospital records and departmental database for consecutive, treatment-naïve patients with CTEPH diagnosed between 1st January 2001 and 30th November 2014 and followed up till 30th November 2015 at the Sheffield Pulmonary Vascular Disease Unit and collected in the ASPIRE registry. Patients with suspected CTEPH undergo systematic evaluation but formal pulmonary angiography is only performed when other imaging modalities such as CTPA, MR imaging and nuclear medicine imaging are non-diagnostic. <h3>Results</h3> 592 patients, mean age (± standard deviation), 65 ± 22 years, mean pulmonary arterial pressure 48 ± 13 mmHg and median pulmonary vascular resistance 480 ± 463 dynes/sec/cm<sup>-5</sup> were identified and followed for 4.3 ± 3.2 years. 5 year survival was significantly (p &lt; 0.001) better in CTEPH-surgical-operated (n = 279) at 82.9 ± 3.1% compared to CTEPH-surgical-not-operated (n = 206) at 44.4 ± 5% (66.7 ± 9.1% patient choice, 39.4 ± 6% comorbidities) and 53.4 ± 5.8% in CTEPH-non-surgical (n = 107). Only 4% of the patients in our study were investigated with conventional pulmonary angiography.The median time to PEA surgery from diagnosis was 10.2 months and did not affect long term survival (p = 0.52). <h3>Conclusions</h3> For operable patients with CTEPH pulmonary endarterectomy is associated with an excellent long term outcome, the long-term survival of patients with surgical disease who decline surgery is significantly better than historically reported and that a non-invasive multimodality imaging approach can be used to assess patients with suspected CTEPH. Furthermore there is no time from diagnosis to surgery which predicts outcome.
P1.01-035 Trends, Patterns of Treatment and Outcomes in Non-Small Cell Lung Cancer (NSCLC) as a Second Primary: A National Cancer Data Base (NCDB) Analysis
Authors: Madhusmita Behera, Theresa Gillespie, Yuan Liu, Yaqi Jia, Kristin Higgins, Conor Steuer, Nabil Saba, Dong Shin, Suchita Pakkala, Rathi Pillai, Taofeek Owonikoko, Walter Curran, Chandra Belani, Fadlo Khuri, Suresh Ramalingam
Journal: Journal of Thoracic Oncology (2017)
Outcome of African-American (AA) Multiple Myeloma (MM) Patients after Autologous Stem Cell Transplantation (ASCT): A Single-Center Experience.
Authors: Yin Wu, Olga Goloubeva, Kathleen Ruehle, Saul Yanovich, Aaron P. Rapoport, Gorgun Akpek, Ashraf Z. Badros
Journal: Blood (2008)
P3.01-049 ELF3 Overexpression Leads to Oncogenic Reprogramming of Protein Interactions Exposing Therapeutically Actionable Targets
Authors: Katey Enfield, Sara Rahmati, David Rowbotham, Megan Fuller, Christine Anderson, Jennifer Kennett, Erin Marshall, Raj Chari, Daiana Becker-Santos, Kevin Ng, Calum Macaulay, Stephen Lam, Katerina Politi, William Lockwood, Aly Karsan, Igor Jurisica, Wan Lam
Journal: Journal of Thoracic Oncology (2017)
P3.07-013 Determining EGFR and ALK Status in a Population-Based Cancer Registry: A Natural Language Processing Validation Study
Authors: Bernardo Goulart, Emily Silgard, Christina Baik, Aasthaa Bansal, Mikael Greenwood-Hickman, Annika Hanson, Scott Ramsey, Stephen Schwartz
Journal: Journal of Thoracic Oncology (2017)
P1.04-015 Clinical Application of Virtual Navigated Bronchial Intervention
Authors: Naohiro Kajiwara, Junichi Maeda, Koichi Yoshida, Masaru Hagiwara, Tetsuya Okano, Masatoshi Kakihana, Tatsuo Ohira, Norihiko Ikeda
Journal: Journal of Thoracic Oncology (2017)
Sequences in Intron 51 of the VWF Gene Target Promoter Activation to a Subset of Lung Endothelial Cells in Transgenic Mice.
Authors: Nadia Jahroudi, Marjan Nassiri, Molly S. Stitt, Karla Wasserloos, Simon C. Watkins, Bruce R. Pitt, Ann M. Kleinschmidt
Journal: Blood (2006)
The AG Genotype of the Wilms Tumor-1 rs16754 SNP Is Associated with Poor Outcome in Pediatric AML Patients Treated with Stem Cell Transplantation but Not in Adults
Authors: Hala Abalkhail, Hassan El-Solh, Amal Alseraihy, Mouhab Ayas, Ali Al-Ahmari, Asim F Belgaumi, Abdullah Al-Jefri, Ola Altombakty, Mohammed Toulimat, Fahed Almhareb, Naeem A. Chaudhri, Claudia Ulrike Walter, Mahmoud Aljurf, Maher Albitar
Journal: Blood (2011)